Aspirin and clopidogrel high on‐treatment platelet reactivity and genetic predictors in peripheral arterial disease
- 7 February 2018
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 91 (7) , 1308-1317
Abstract
Objectives: Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on‐treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD).Background: The association of aspirin and clopidogrel HoTPR with outcomes in PAD remains unclear.Methods: This is a prospective cohort study of patients with angiographically documented PAD involving carotid and lower extremity arteries. Aspirin and clopidogrel HoTPR (using the VerifyNow Assay) and associated genetic predictors were compared to clinical outcomes. The primary end‐point was a composite of major adverse cardiovascular events: all‐cause mortality, myocardial infarction, stroke, target vessel revascularization (TVR) and limb‐loss in patients who underwent extremity intervention.Results: The study was stopped prematurely due to slow patient enrolment. Of 195 patients enrolled, the primary analysis was performed in 154 patients taking both drugs. Aspirin HoTPR was present in 31 (20%) and clopidogrel HoTPR in 76 (49%) patients. There was a trend toward more primary composite outcome events with PRU ≥ 235 (52% freedom‐from‐event rate vs. 70% for PRU < 235; P = 0.09). TVR was higher in those with PRU ≥ 235 (20 vs. 6%, unadjusted P = 0.02). There was no association between aspirin HoTPR and combined outcomes. Single nucleotide polymorphisms in serum paraoxonase/arylesterase 1 (PON1) gene was associated with aspirin HoTPR (P = 0.005) while SNP in phospholipase A2, group III (PLA2G3) gene was associated with clopidogrel HoTPR (P = 0.002).Conclusion: Clopidogrel HoTPR was significantly associated with TVR, while aspirin HoTPR was not associated with adverse clinical outcomes in patients with PAD.Keywords
Funding Information
- National Institutes of Health (R01 HL085727, R01 HL137228, R01 HL085844)
- Robert Wood Johnson Foundation (CTSC KL2)
- National Center for Advancing Translational Sciences (UL1 TR000002, CTSC KL2, UL1 TR001860)
This publication has 43 references indexed in Scilit:
- Recent advances in the pharmacogenetics of clopidogrelHuman Genetics, 2011
- Pharmacogenomics of clopidogrel: Evidence and perspectivesThrombosis Research, 2011
- Variability and persistence of aspirin response in lower extremity peripheral arterial disease patientsJournal of Vascular Surgery, 2011
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Comparison of Different Methods to Evaluate the Effect of Aspirin on Platelet Function in High-Risk Patients With Ischemic Heart Disease Receiving Dual Antiplatelet TreatmentAmerican Journal of Clinical Pathology, 2007
- Aspirin resistance and a single geneThe American Journal of Cardiology, 2005
- Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialAmerican Heart Journal, 2004
- Association of two silent polymorphisms of platelet glycoprotein la/lla receptor with risk of myocardial infarction: a case-control studyThe Lancet, 1999
- Human Serum ParaoxonaseGeneral Pharmacology: The Vascular System, 1998